Some former studies indicated that expression of c-MYC protein was frequently observed and was associated with poor outcome in PCNS-DLBCL in comparison to systemic DLBCL.[21,22] The proportion of c-MYC expression ranged from 30% to 90% of cases reported by previous literature.[23,24] In our study, 32.7% of cases presented with c-MYC expression, which was similar to systematic DLBCL. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.